News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in Inhibikase Therapeutics (IKT), totaling 5,810,487 shares as of June 30, 2026. This stake includes 3,108,624 shares acquirable through convertible securities within sixty days. The …
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.9% in Inhibikase Therapeutics, Inc. (IKT) through warrants. This stake, totaling 10,320,875 shares, is primarily held by the Master Fund through various pre-funded and common warrants, …
Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …
The fund is Robinhood’s second to offer everyday investors the ability to invest in private companies. Continue Reading
Sharemaestro market context Trend signal active 52 weeks -19.5%Shinhan Securities achieved a 19.7% return on equity in the first half of the year, driven by a diversified revenue strategy. The company successfully converted stock market investors into wealth management clients, significantly increasing fee income and assets under management. Additionally, its investment banking …
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Robinhood Market(NASDAQ:HOOD) CIO Stephanie Guild says the artificial intelligence boom may keep driving stocks to fresh records, but its enormous appetite for capital is creating a new …
Sharemaestro market context Trend signal active 52 weeks -19.5%Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …
* Shinhan Financial press release [https://seekingalpha.com/filing/309951294] (SHG [https://seekingalpha.com/symbol/SHG]): Q2 Non-GAAP EPS ₩3750. * Revenue actual for Q2 2026 was ₩25.06T compared to ₩23.22T in Q2 2025. * Net interest income for Q2 2026 reached ₩3.13T. * Approved a ₩700B share buyback and cancellation plan. …
Sharemaestro market context Trend signal active 52 weeks +64.9%Key insights: Tech companies such as Robinhood and OpenAI are counting on AI agents to provide more insights into consumers' financial lives, and sometimes, self-execute payments and rebalance investment portfolios. Some fear that retail banking is the next logical evolution for agent-led automation. What's …
Sharemaestro market context Trend signal active 52 weeks -19.5%Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …
Shinhan Financial Group closed at $75.81, just 2.2% below its 52-week high, as a long-running Trend Signal stayed active despite lighter-than-average participation.
Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …
This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.
Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …
Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …
This article first appeared on GuruFocus. Robinhood Markets (NASDAQ:HOOD) launched its second venture fund, listing Robinhood Ventures Fund II (RVII) on the NYSE after pricing 8 million shares at $25 each. The company said the offering raised $225.5 million. Robinhood shares were up 3.94% …
Sharemaestro market context Trend signal active 52 weeks -19.5%(Updates with company response in the last two paragraphs.)Robinhood Markets (HOOD) plans to accelerate the pace of debuts for its publicly traded closed-end funds after its first two attempts to make private firms more accessible to its retail customers, Bloomberg reported Silver Upgrade to …
Sharemaestro market context Trend signal active 52 weeks -19.5%Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are …
Listen and subscribe to Power Players with Brian Sozzi on Apple Podcasts, Amazon Music, Spotify, YouTube, or wherever you find your favorite podcasts. The not-in-my-backyard, anti-AI data center crew has at least one prominent supporter: Robinhood (HOOD) co-founder and space racer Baiju Bhatt. Bhatt …
Sharemaestro market context Trend signal active 52 weeks -19.5%By Manya Saini Aug 13 (Reuters) - Robinhood's second venture fund debuted on Thursday, giving retail investors access to early-stage startups that have traditionally been out of reach for all but venture capital firms and wealthy investors. The fintech company raised $225.5 million in …
Sharemaestro market context Trend signal active 52 weeks -19.5%When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. …
Oppenheimer has reiterated its Buy rating on Inhibikase Therapeutics (IKT.US), maintaining a target price of $5. This indicates continued confidence from the firm in the company's prospects.
Robinhood co-founder Baiju Bhatt explains to Yahoo Finance Executive EditorBrian Sozzi his $275 million plan for Cowboy Space Corporation to build its own rockets and launch AI-powering data centers into space by 2028. Video Transcript 0:00 spk_0 We're building our own rocket program to …
Sharemaestro market context Trend signal active 52 weeks -19.5%Search by ticker symbol or company name and select a result to open its chart.